Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that acts in the proximal renal tubules to reduce glucose reabsorption, promoting urinary glucose excretion, and also reduces sodium reabsorption.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Farxiga
Drug type
Small molecule
Targets
sodium-glucose cotransporter 2 (SLC5A2)
Mechanism
Inhibitor of sodium-glucose cotransporter 2 (SLC5A2)
From the indications section of the FDA label (version of Jul 10, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.